Skip to main content

 

Trending Tickers

T

Macquarie Reaffirms “Buy” Rating for AT&T Inc. (T)

Macquarie reaffirmed their buy rating on shares of AT&T Inc. (NYSE:T) in a research note released on Sunday morning. The brokerage currently has a $48.00 price target on the stock. The brokerage currently has a $48.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and fourteen have given a buy rating to the company’s stock. The company has a market cap of $254.54 billion, a PE ratio of 17.63 and a beta of 0.37. The original version of this story can be read at https://www.com-unik.info/2017/01/22/macquarie-reaffirms-buy-rating-for-att-inc-t.html. The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 1st. Yang bought 27,129 shares of the firm’s stock in a transaction on Tuesday, October 25th. Capital International Investors now owns 17,502,280 shares of the company’s stock valued at $756,274,000 after buying an additional 12,209,300 shares in the last quarter. The Company offers communications and digital entertainment services in the United States and the world.

IBM

Miller Howard Investments Inc. NY Takes Position in International Business Machines Corp. (IBM)

The firm bought 400,936 shares of the technology company's stock, valued at approximately $63,689,000. Capital Research Global Investors now owns 7,135,471 shares of the technology company's stock worth $1,083,022,000 after buying an additional 3,194,471 shares in the last quarter. Now owns 55,476,336 shares of the technology company's stock worth $8,420,198,000 after buying an additional 1,216,940 shares in the last quarter. Capital World Investors now owns 5,322,000 shares of the technology company's stock worth $807,773,000 after buying an additional 972,000 shares in the last quarter. Alliancebernstein L.P. now owns 2,653,828 shares of the technology company's stock worth $402,798,000 after buying an additional 830,006 shares in the last quarter. BlackRock Fund Advisors now owns 13,451,769 shares of the technology company's stock worth $2,041,709,000 after buying an additional 806,207 shares in the last quarter. Gave the stock a "Buy" rating in a report on Monday, November 21st. Zacks Investment Research upgraded shares of International Business Machines Corp. Stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $162.44, for a total transaction of $342,261. Following the completion of the transaction, the insider now directly owns 4,147 shares of the company's stock, valued at approximately $673,638. Following the transaction, the insider now directly owns 6,812 shares of the company's stock, valued at $1,027,249. …

MTG

MGIC Investment Corp. (MTG) Given “Buy” Rating at BTIG Research

BTIG Research reissued their buy rating on shares of MGIC Investment Corp. Gave the stock a hold rating in a report on Friday, November 11th. FBR & Co restated an outperform rating and issued a $11.00 price target on shares of MGIC Investment Corp. From a hold rating to a strong-buy rating and set a $9.25 price target for the company in a report on Wednesday, October 5th. Finally, Deutsche Bank AG upgraded MGIC Investment Corp. From a hold rating to a buy rating and increased their target price for the company from $9.00 to $12.00 in a research note on Monday, December 12th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. ILLEGAL ACTIVITY NOTICE: "MGIC Investment Corp. Given"Buy" Rating at BTIG Research" was reported by Community Financial News and is the sole property of of Community Financial News. What are top analysts saying about MGIC Investment Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MGIC Investment Corp.

REGN

Regeneron Pharmaceuticals Inc. (REGN) Stock Rating Reaffirmed by JPMorgan Chase & Co.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Sunday. They presently have a $440.00 price objective on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s target price would indicate a potential upside of 21.36% from the stock’s previous close. They presently have a $440.00 price objective on the biopharmaceutical company’s stock. Cowen and Company set a $430.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Sunday, October 30th. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $482.27. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.29 billion. The legal version of this report can be viewed at https://www.com-unik.info/2017/01/22/regeneron-pharmaceuticals-inc-regn-stock-rating-reaffirmed-by-jpmorgan-chase-co.html. Goldstein sold 2,125 shares of the business’s stock in a transaction dated Monday, November 14th. BlackRock Fund Advisors now owns 2,290,395 shares of the biopharmaceutical company’s stock worth $920,785,000 after buying an additional 68,436 shares during the last quarter. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. and related companies.


No results

Please try a less specific search term, then narrow the results as necessary. You may also be able to retrieve more results by clearing the search filter shown above. You may also be able to retrieve more results by clearing one or more of the search filters shown above.


  Report sparse topic areas

We strive to collect and review the most authoritative sources for original research and scholarly blogging across a multitude of topics. If you are having difficulties finding content in a specific topic area, we want to know!

  Suggest new content

If you are aware of a scholarly blog that discusses the topic of your search, we want to know about it! Your suggestion is appreciated and will be reviewed by our team of researchers and editors.

[[ error.msg ]]